Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer
Status:
Completed
Trial end date:
2020-05-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare progression-free survival (PFS) of patients
with metastatic Luminal B2 breast cancer subtype randomised to treatment with Trastuzumab
Combined With Chemotherapy or Endocrine Therapy.